PDS Biotechnology
PDSB
64 hedge funds and large institutions have $89.3M invested in PDS Biotechnology in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 7 closing their positions.
480% more capital invested
Capital invested by funds: $15.4M → $89.3M (+$73.9M)
380% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $2.51M
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
36% more funds holding
Funds holding: 47 → 64 (+17)
5.72% more ownership
Funds ownership: 18.2% → 23.92% (+5.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.18M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$2.33M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.29M |
| 4 |
Morgan Stanley
New York
|
+$1.47M |
| 5 |
Two Sigma Investments
New York
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$810K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$648K |
| 3 |
Renaissance Technologies
New York
|
-$529K |
| 4 |
NLVP
New Leaf Venture Partners
New York
|
-$348K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$171K |
PDSB Hedge Fund Activity: Q4 2022 in Review
64 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q4 2022, worth a combined $89.3M — up 480% from $15.4M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PDSB positions and 7 closed out — a net gain of 18 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.18M. The largest seller was LPL Financial, cutting an estimated $810K.
- 64 institutional investors held PDS Biotechnology (PDSB) as of Q4 2022, up from 47 in Q3 2022.
- Funds reported $89.3M of PDS Biotechnology stock for Q4 2022, up 480% quarter-over-quarter.
- 25 funds opened new PDS Biotechnology positions in Q4 2022 and 7 closed out, a net change of +18 holders.
- The largest PDS Biotechnology buyer in Q4 2022 was Millennium Management, an estimated $3.18M added.
- The largest PDS Biotechnology seller in Q4 2022 was LPL Financial, an estimated $810K sold.
Based on aggregated 13F filings for Q4 2022.